MedPath
HSA Approval

CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL

SIN16384P

CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL

CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL

November 25, 2021

PHARMA TO MARKET PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMA TO MARKET PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS

Medical Information

L01XC03

xl 01 xc 03

Manufacturer Information

PHARMA TO MARKET PTE. LTD.

Biocon Biologics India Limited (Powder & Solvent)

Active Ingredients

Trastuzumab

440 mg/vial

Trastuzumab

Documents

Package Inserts

CANHERA PI.pdf

Approved: November 25, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.